325 related articles for article (PubMed ID: 17090536)
21. Investigating the purpose of prelamin A processing.
Davies BS; Coffinier C; Yang SH; Barnes RH; Jung HJ; Young SG; Fong LG
Nucleus; 2011; 2(1):4-9. PubMed ID: 21647293
[TBL] [Abstract][Full Text] [Related]
22. Presence and distribution of progerin in HGPS cells is ameliorated by drugs that impact on the mevalonate and mTOR pathways.
Clements CS; Bikkul MU; Ofosu W; Eskiw C; Tree D; Makarov E; Kill IR; Bridger JM
Biogerontology; 2019 Jun; 20(3):337-358. PubMed ID: 31041622
[TBL] [Abstract][Full Text] [Related]
23. Genomic instability and DNA damage responses in progeria arising from defective maturation of prelamin A.
Musich PR; Zou Y
Aging (Albany NY); 2009 Jan; 1(1):28-37. PubMed ID: 19851476
[TBL] [Abstract][Full Text] [Related]
24. Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice.
Fong LG; Ng JK; Meta M; Coté N; Yang SH; Stewart CL; Sullivan T; Burghardt A; Majumdar S; Reue K; Bergo MO; Young SG
Proc Natl Acad Sci U S A; 2004 Dec; 101(52):18111-6. PubMed ID: 15608054
[TBL] [Abstract][Full Text] [Related]
25. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
Glynn MW; Glover TW
Hum Mol Genet; 2005 Oct; 14(20):2959-69. PubMed ID: 16126733
[TBL] [Abstract][Full Text] [Related]
26. Abolishing the prelamin A ZMPSTE24 cleavage site leads to progeroid phenotypes with near-normal longevity in mice.
Wang Y; Shilagardi K; Hsu T; Odinammadu KO; Maruyama T; Wu W; Lin CS; Damoci CB; Spear ED; Shin JY; Hsu W; Michaelis S; Worman HJ
Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35197292
[TBL] [Abstract][Full Text] [Related]
27. Increased progerin expression associated with unusual LMNA mutations causes severe progeroid syndromes.
Moulson CL; Fong LG; Gardner JM; Farber EA; Go G; Passariello A; Grange DK; Young SG; Miner JH
Hum Mutat; 2007 Sep; 28(9):882-9. PubMed ID: 17469202
[TBL] [Abstract][Full Text] [Related]
28. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts.
Bikkul MU; Clements CS; Godwin LS; Goldberg MW; Kill IR; Bridger JM
Biogerontology; 2018 Dec; 19(6):579-602. PubMed ID: 29907918
[TBL] [Abstract][Full Text] [Related]
29. Accumulation of distinct prelamin A variants in human diploid fibroblasts differentially affects cell homeostasis.
Candelario J; Borrego S; Reddy S; Comai L
Exp Cell Res; 2011 Feb; 317(3):319-29. PubMed ID: 20974128
[TBL] [Abstract][Full Text] [Related]
30. Lamin A, farnesylation and aging.
Reddy S; Comai L
Exp Cell Res; 2012 Jan; 318(1):1-7. PubMed ID: 21871450
[TBL] [Abstract][Full Text] [Related]
31. Different prelamin A forms accumulate in human fibroblasts: a study in experimental models and progeria.
Dominici S; Fiori V; Magnani M; Schena E; Capanni C; Camozzi D; D'Apice MR; Le Dour C; Auclair M; Caron M; Novelli G; Vigouroux C; Maraldi NM; Lattanzi G
Eur J Histochem; 2009; 53(1):43-52. PubMed ID: 19351612
[TBL] [Abstract][Full Text] [Related]
32. Autophagic degradation of farnesylated prelamin A as a therapeutic approach to lamin-linked progeria.
Cenni V; Capanni C; Columbaro M; Ortolani M; D'Apice MR; Novelli G; Fini M; Marmiroli S; Scarano E; Maraldi NM; Squarzoni S; Prencipe S; Lattanzi G
Eur J Histochem; 2011 Oct; 55(4):e36. PubMed ID: 22297442
[TBL] [Abstract][Full Text] [Related]
33. New Lmna knock-in mice provide a molecular mechanism for the 'segmental aging' in Hutchinson-Gilford progeria syndrome.
Jung HJ; Tu Y; Yang SH; Tatar A; Nobumori C; Wu D; Young SG; Fong LG
Hum Mol Genet; 2014 Mar; 23(6):1506-15. PubMed ID: 24203701
[TBL] [Abstract][Full Text] [Related]
34. Status of treatment strategies for Hutchinson-Gilford progeria syndrome with a focus on prelamin: A posttranslational modification.
Chen X; Yao H; Andrés V; Bergo MO; Kashif M
Basic Clin Pharmacol Toxicol; 2022 Oct; 131(4):217-223. PubMed ID: 35790078
[TBL] [Abstract][Full Text] [Related]
35. Farnesylated lamins, progeroid syndromes and farnesyl transferase inhibitors.
Rusiñol AE; Sinensky MS
J Cell Sci; 2006 Aug; 119(Pt 16):3265-72. PubMed ID: 16899817
[TBL] [Abstract][Full Text] [Related]
36. A homozygous ZMPSTE24 null mutation in combination with a heterozygous mutation in the LMNA gene causes Hutchinson-Gilford progeria syndrome (HGPS): insights into the pathophysiology of HGPS.
Denecke J; Brune T; Feldhaus T; Robenek H; Kranz C; Auchus RJ; Agarwal AK; Marquardt T
Hum Mutat; 2006 Jun; 27(6):524-31. PubMed ID: 16671095
[TBL] [Abstract][Full Text] [Related]
37. A mutation abolishing the ZMPSTE24 cleavage site in prelamin A causes a progeroid disorder.
Wang Y; Lichter-Konecki U; Anyane-Yeboa K; Shaw JE; Lu JT; Östlund C; Shin JY; Clark LN; Gundersen GG; Nagy PL; Worman HJ
J Cell Sci; 2016 May; 129(10):1975-80. PubMed ID: 27034136
[TBL] [Abstract][Full Text] [Related]
38.
Spear ED; Hsu ET; Nie L; Carpenter EP; Hrycyna CA; Michaelis S
Dis Model Mech; 2018 Jul; 11(7):. PubMed ID: 29794150
[TBL] [Abstract][Full Text] [Related]
39. Dysregulated interactions between lamin A and SUN1 induce abnormalities in the nuclear envelope and endoplasmic reticulum in progeric laminopathies.
Chen ZJ; Wang WP; Chen YC; Wang JY; Lin WH; Tai LA; Liou GG; Yang CS; Chi YH
J Cell Sci; 2014 Apr; 127(Pt 8):1792-804. PubMed ID: 24522183
[TBL] [Abstract][Full Text] [Related]
40. Targeting RAS-converting enzyme 1 overcomes senescence and improves progeria-like phenotypes of ZMPSTE24 deficiency.
Yao H; Chen X; Kashif M; Wang T; Ibrahim MX; Tüksammel E; Revêchon G; Eriksson M; Wiel C; Bergo MO
Aging Cell; 2020 Aug; 19(8):e13200. PubMed ID: 32910507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
